P959 Dose escalated vedolizumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program
Judith McNamara(Liverpool Hospital), Susan J. Connor(Liverpool Hospital), Graham Radford‐Smith(QIMR Berghofer Medical Research Institute), Kate D. Lynch(Royal Adelaide Hospital), Ian C. Lawrance(The University of Western Australia), Joseph L. Pipicella(Ingham Institute), Watson Ng(Liverpool Hospital), Richard B. Gearry(Waitaki Biosciences (New Zealand)), Simon Ghaly(UNSW Sydney), Jakob Begun(Translational Research Institute), Basheer Alshiwanna(Liverpool Hospital), Walter R. Wilson(Lyell McEwin Hospital), Jordan Andrews(Health Net), Gregor Walker(The University of Queensland), Michael Schultz
Cited by 0
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Prevention of Infective Endocarditis
|Circulation|2007|2.8k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k